| pubmed-article:9726437 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C0030705 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C0016360 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C1527249 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C0348016 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:9726437 | lifeskim:mentions | umls-concept:C1705294 | lld:lifeskim |
| pubmed-article:9726437 | pubmed:issue | 8 | lld:pubmed |
| pubmed-article:9726437 | pubmed:dateCreated | 1998-11-19 | lld:pubmed |
| pubmed-article:9726437 | pubmed:abstractText | A phase II trial was carried out by the Grupo Oncologico Cooperativo del Sur (G.O.C.S.) to assess the efficacy and toxicity of a biochemical modulation of 5-fluorouracil (5-FU) by i.v. pretreatment with interferon (IFN)-alpha2b in patients with advanced colorectal carcinoma refractory to previous therapy with 5-FU modulated by methotrexate (MTX) or leucovorin (LV) or both. Between January 1993 and October 1995, 34 patients were entered on the study. The treatment was IFN-alpha2b 5 x 10(6)/m2 IU in a 1-h i.v. infusion, followed immediately by 5-FU 600 mg/m2 i.v. bolus injection. Courses were repeated weekly until observation of progressive disease or severe toxicity. One patient could not be assessed for response. Objective regression was observed in 2 of 33 patients (6%, 95% confidence interval, 0%-14%). No patient achieved a complete response. Two patients had partial responses (6%). No change was recorded in 14 patients (41%), and progressive disease occurred in 17 (52%). The median time to treatment failure was 3 months, and the median survival was 5 months. Toxicity was within acceptable limits. The main side effects were mucositis and diarrhea. Four episodes of grade 2 stomatitis were observed, causing dosage modifications. The most frequent toxic effects attributable to IFN-alpha2b were mild fatigue and fever. In conclusion, second-line therapy with i.v. IFN-alpha2b preceding 5-FU has shown an interesting profile of activity in a patient population with clearly unfavorable characteristics. From this perspective, further appropriately designed studies are needed to identify the greatest potential of IFN-alpha2b as a modulator of 5-FU. | lld:pubmed |
| pubmed-article:9726437 | pubmed:language | eng | lld:pubmed |
| pubmed-article:9726437 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:9726437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:9726437 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:9726437 | pubmed:month | Aug | lld:pubmed |
| pubmed-article:9726437 | pubmed:issn | 1079-9907 | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:AmatoSS | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:RodríguezRR | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:PérezJ EJE | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:LeoneB ABA | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:VallejoC TCT | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:MarroneNN | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:BarbieriM RMR | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:LacavaJ AJA | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:MachiavelliM... | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:LanghiM JMJ | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:RomeroA OAO | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:OrtizE HEH | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:DomínguezM... | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:Romero... | lld:pubmed |
| pubmed-article:9726437 | pubmed:author | pubmed-author:Romero... | lld:pubmed |
| pubmed-article:9726437 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:9726437 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:9726437 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:9726437 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:9726437 | pubmed:pagination | 565-9 | lld:pubmed |
| pubmed-article:9726437 | pubmed:dateRevised | 2011-11-17 | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:meshHeading | pubmed-meshheading:9726437-... | lld:pubmed |
| pubmed-article:9726437 | pubmed:year | 1998 | lld:pubmed |
| pubmed-article:9726437 | pubmed:articleTitle | Biomodulation with sequential intravenous IFN-alpha2b and 5-fluorouracil as second-line treatment in patients with advanced colorectal cancer. | lld:pubmed |
| pubmed-article:9726437 | pubmed:affiliation | Grupo Oncológico Cooperativo del Sur, Neuquén, República Argentina. | lld:pubmed |
| pubmed-article:9726437 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:9726437 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:9726437 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:9726437 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
